迷幻药医学化中的知识空白：临床前和神经影像学机制
Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms.
作者信息
McCulloch Drummond E-Wen, Lopez Juan Pablo, Dalla Christina, Castrén Eero, Erritzoe David, Frokjaer Vibe G, Lundberg Johan, Preller Katrin H, Fisher Patrick MacDonald, Knudsen Gitte Moos
机构信息
Neurobiology Research Unit, Rigshospitalet, and University of Copenhagen, Copenhagen, Denmark.
Department of Neuroscience, Karolinska Institute, Solna, 171 77, Sweden.
出版信息
Neurosci Appl. 2023 Dec 15;3:103929. doi: 10.1016/j.nsa.2023.103929. eCollection 2024.
Classical psychedelic drugs, e.g., psilocybin and LSD, stimulate the serotonin 2A receptor (5-HT2AR) and have recently been intensely investigated for their clinical effects in various brain disorders. At the ECNP "New Frontiers meeting" in March 2023, scientific experts in psychedelics met to identify key knowledge gaps in the mechanism of action of psychedelics as investigated using preclinical models and clinical neuroimaging. Key themes included the development of appropriate behavioural models for measuring acute and persisting effects, dose optimisation, molecular mechanisms of action, sex differences, and the acute and persisting effects of psychedelics on neurotransmitter release and functional brain activity.
经典致幻药物，如裸盖菇素和麦角酸二乙酰胺（LSD），可刺激5-羟色胺2A受体（5-HT2AR），最近人们对其在各种脑部疾病中的临床效果进行了深入研究。在2023年3月举行的欧洲神经精神药理学会（ECNP）“新前沿会议”上，致幻剂领域的科学专家齐聚一堂，以确定在使用临床前模型和临床神经影像学研究致幻剂作用机制方面的关键知识空白。关键主题包括开发用于测量急性和持续效应的适当行为模型、剂量优化、分子作用机制、性别差异，以及致幻剂对神经递质释放和大脑功能活动的急性和持续影响。
Zotero 插件